Patterns and Longitudinal Changes in the Practice of Breast Cancer Radiotherapy in Korea: Korean Radiation Oncology Group 22-01
- 주제(키워드) Breast Neoplasms , Practice Patterns , Physicians' , Radiotherapy , Republic ofKorea , Surveys and Questionnaires
- 주제(기타) Oncology
- 설명문(일반) [Park, Hae Jin] Hanyang Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Kim, Kyubo] Ewha Womans Univ, Dept Radiat Oncol, Coll Med, 1071 Anyangcheon Ro, Seoul 07985, South Korea; [Kim, Yong Bae; Chang, Jee Suk] Yonsei Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Shin, Kyung Hwan] Seoul Natl Univ, Dept Radiat Oncol, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- OA유형 gold
- 발행기관 KOREAN BREAST CANCER SOC
- 발행년도 2023
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000208592
- 본문언어 영어
- Published As https://doi.org/10.4048/jbc.2023.26.e15
- PubMed 37272243
초록/요약
Purpose: We aimed to analyze contemporary practice patterns in breast cancer radiotherapy (RT) and assess longitudinal changes over five years in Korea. Methods: In 2022, a nationwide survey was conducted among board-certified radiation oncologists. The survey consisted of 44 questions related to six domains: hypofractionated (HypoFx) whole breast RT, accelerated partial breast RT (APBI), regional nodal irradiation (RNI), RT for ductal carcinoma in situ (DCIS), postmastectomy RT (PMRT), and tumor bed boost. Results: Seventy radiation oncologists from 61 (out of 101; 60%) institutions participated in the survey. HypoFx RT was used by 62 respondents (89%), a significant increase from 36% in 2017. HypoFx RT is commonly administered at 40-42.5 Gy in 15-16 fractions. APBI was used by 12 respondents (17%), an increase from 5% in 2017. The use of RNI did not change significantly: & GE; pN2 (6%), & GE; pN1 (33%), and & GE; pN1 with pathological risk factors (61%). However, indications for internal mammary lymph node (IMN) irradiation have expanded. In particular, the rates of routine treatment of IMN (11% from 6% in 2017) and treatment in cases of & GE; pN2 (27% from 14% in 2017) have doubled; however, the rate of treatment for only IMN involvement, identified on imaging, has decreased from 47% in 2017 to 31%. For DCIS, the use of HypoFx RT increased from 25% in 2017 to 75%, and the rate of RT omissions after breast-conserving surgery (BCS) decreased from 48% in 2017 to 38%. The use of HypoFx RT for PMRT increased from 8% in 2017 to 36%. Conclusion: The adoption of HypoFx RT after BCS for invasive breast cancer and DCIS has increased significantly, whereas the use of HypoFx PMRT has increased moderately since 2017. However, further studies are required to determine the optimal use of RNI.
more